Zucara is developing ZT-01, the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in diabetes patients. Current therapies are reactive, “rescuing” patients from potentially dangerous low blood sugar levels. ZT-01 offers significant benefit to diabetes patients by preventing hypoglycemia.

ZT-01 (an octapeptide analog) works by blocking the activity of somatostatin, a pancreatic hormone that is not properly regulated in insulin-dependent diabetes. Blocking somatostatin restores glucagon secretion, which restores blood glucose levels.

Night-time Administration to Prevent Overnight Hypoglycemia

ZT-01 (an octapeptide analog) works by blocking the activity of somatostatin, a pancreatic hormone that is not properly regulated in insulin-dependent diabetes. Blocking somatostatin restores glucagon secretion, which restores blood glucose levels.

"Hypoglycemia is clearly an under-recognized risk factor for death and cardiovascular disease in people with diabetes“¹

Each year in the US alone, hypoglycemia is responsible for approximately²

1.4M emergency hospital visits/ hospitalizations

3,000 deaths


Global Insulin Using Population (M) ▶️ ROW ▶️ EU ▶️ US

Night-time Administration to Prevent Overnight Hypoglycemia

ZT-01, Somatostatin Receptor Type 2 (SSRT2) Antagonist

Blood glucose level

Glucagon secretion

Glucagon secretion

WT-01

50% of hypoglycemia events happen overnight, when patients feel most vulnerable

up to 27% of unexplained deaths in T1D involves night-time hypoglycemia³

8.3M 77% 77% 20% = $550M $3.8B

Addressable market Worried about night-time hypoglycemia Price/year: US$3,000-$4,800 Uptake: 10-20% = US market Global market

6.1M 77% 77% 10% = $440M $1.4B

T2D intensively managed

T2D Basal only

14.7

6.8

1.8 1.2 5.3

2.0 2.2 1.9

4.4

T1D

1.8 1.2

T2D Basal only

Significant Market Opportunity

Glucagon secretion

ZT-01 Efficacy Results
Highlights

- Improved glucagon counterregulation with treatment
- Resistance to insulin-induced hypoglycemia
- 8 studies conducted across 3 models with ZT-01 efficacy replicated in 2 independent labs

Attractive profile for rapidly generating human PoC, with financing secured to the clinic


- Pre-IND meeting
- Clinical plan
- In vivo safety & efficacy
- Select candidate
- Validation
- PoC
- $2.3M
- $4.8M
- $10-15M
- Series A Financing
- Phase 1
- Phase 2

Leadership

Michael Midmer
Chief Executive Officer

Michael Riddell
Chair, Scientific Advisory Board

Richard Liggins
Chief Scientific Officer

Luc Mainville
Chair of Board
CFO, Valeo Pharma

Claude Piche
Independent Director
CEO, Locemia Solutions

Contact

Michael Midmer, CEO
Zucara Therapeutics Inc.
mmidmer@zucara.ca
MaRS Centre, Suite 1300
661 University Avenue
Toronto, ON M5G 0B7